The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This analysis examines access to, and consumers ability to find information on, a new twice annual long-acting PrEP drug during the first ACA open enrollment period since its approval. Despite the drug widely being considered a major advance, early evidence suggests that insurance coverage and benefit design decisions may create barriers to access.
On February 14, 2026, CMS released a dataset with provider-level spending data that the agency suggests could be used to identify unusual billing patterns for specific services, states, or providers. This policy watch describes what the data include, what they exclude, and how they could potentially lead to mistaken conclusions given the limitations of the data.
While issues of health care costs and affordability may not be at the forefront of this year’s election issues, they remain a major concern among the public. About a quarter of Americans say they or a family member struggled to pay their medical bills just in the past year, and in recent KFF polling, voters said that health care affordability was very important to discuss in the election.KFF’s new brief describes the health cost and…
In 2025, Medicare beneficiaries will pay no more than $2,000 out of pocket for prescription drugs covered under Part D, Medicare’s outpatient drug benefit, due to a provision in the Inflation Reduction Act of 2022. This analysis examines how many Medicare Part D enrollees spent $2,000 or more out of pocket in 2021 and over multiple years, both nationally and at the state level, to show how many people over time could benefit from the…
Under the Inflation Reduction Act, the federal government for the first time will negotiate directly with drug companies to determine the prices that Medicare will pay for certain high expenditure drugs covered under Medicare Part D (starting in 2026) and Part B (starting in 2028). Part D covers retail prescription drugs and Part B covers physician-administered medications. This new requirement is the culmination of years of debate among lawmakers in Congress, and the Centers for…
This brief highlights some of the key federal agencies and offices that play a role in making Medicare work and, to the extent possible, describes the recent staffing and organizational changes made by the Trump administration that could affect the operations of Medicare in the future.
Under estate recovery, state Medicaid programs are required to recover the costs of long-term care and related hospital and prescription drug services for enrollees ages 55 and older. KFF examines the wide variation in estate recovery practices across states as well as the criticisms of this policy, which have led to federal proposals to modify or reduce it.
KFF's latest Tracking Poll finds that one-third of the public report using AI chatbots for health information and advice in the past year. And a federal judge suspended, for now, the appointments of thirteen members of ACIP, halting a scheduled meeting and staying recent, widely debated, changes to the childhood vaccine schedule.
This chart collection explores how health spending is expected to grow in coming years, with a look at growth in prescription drug spending, out-of-pocket spending, and related trends.
This brief analyzes leading federal approaches to address Medicaid prescription drug spending, discusses (where available) a range of cost estimates for each policy, and assesses what drives those estimates or where there is uncertainty in them.
© 2026 KFF